Potential application of grape derived polyphenols in huntington's disease

Translational Neuroscience

Volumn 1, Issue 2, 2010, Pages 95-100

  Wang, Jun ^a   Pfleger, Cathie M ^a   Friedman, Lauren ^a   Vittorino, Roselle ^a   Zhao, Wei ^a   Qian, Xianjuan ^a   Conley, Lindsay ^a   Ho, Lap ^a,c   Pasinetti, Giulio M ^a,b,c  

^a Department of Neurology ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Abnormal protein aggregation Huntingtin protein; Drosophila; Motor function; Neurological disorders; PC 12 cell; R6 2 mouse

Indexed keywords

GRAPE SEED EXTRACT; HUNTINGTIN; PHENOL DERIVATIVE; POLYGLUTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DROSOPHILA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT;

EID: 79952338055     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/v10134-010-0022-y     Document Type: Article

References (39)

1. MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993 Mar 26;72(6):971-83. (Pubitemid 23110238)
2. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997 Aug 8;90(3):537-48. (Pubitemid 27347243)
3. Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995 Nov 23;378(6555):403-6.
4. Walker FO. Huntington's disease. Lancet 2007 Jan 20;369(9557):218-28. (Pubitemid 46107685)
5. Duff K, Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC. Psychiatric symptoms in Huntington's disease before diagnosis: The predict-HD study. Biol Psychiatry 2007 Dec 15;62(12):1341-6. (Pubitemid 350180721)
6. Johnson SA, Stout JC, Solomon AC, Langbehn DR, Aylward EH, Cruce CB, et al. Beyond disgust: Impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007 Jul;130(Pt 7):1732-44. (Pubitemid 47343802)
7. Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007 Apr 9;45(8):1767-76. (Pubitemid 46386118)
8. Penney JB, Jr., Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5(2):93-9. (Pubitemid 20166182)
9. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997 Aug 8;90(3):537-48. (Pubitemid 27347243)
10. Gillian Bates, Peter S.Harper, Lesley Jones. Huntington's DiseaseThird Edition. Oxford University Press; 2002.
11. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000;101(1):57-66.
12. Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 2002 Nov 1;11(23):2905-17.
13. Watase K, Weeber EJ, Xu B, Antalffy B, Yuva-Paylor L, Hashimoto K, et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 2002 Jun 13;34(6):905-19. (Pubitemid 34722281)
14. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998 Oct 2;95(1):55-66.
15. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003 Jan 23;421(6921):373-9. (Pubitemid 36157935)
16. Kazantsev A, Walker HA, Slepko N, Bear JE, Preisinger E, Steffan JS, et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet 2002 Apr;30(4):367-76.
17. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proceedings of the National Academy of Sciences of the United States of America 2003 May 13;100(10):5950-5. (Pubitemid 36576913)
18. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 2006 Sep 15;15(18):2743-51. (Pubitemid 44400401)
19. Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, et al. Grapederived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J Neurosci 2008 Jun 18;28(25):6388-92.
20. Ono K, Condron MM, Ho L, Wang J, Zhao W, Pasinetti GM, et al. Effects of Grape Seed-derived Polyphenols on Amyloid {beta}-Protein Selfassembly and Cytotoxicity. J Biol Chem 2008 Nov 21;283(47):32176-87.
21. Ho L, Yemul S, Wang J, Pasinetti G. Grape seed polyphenolic extract (GSE) as a novel therapeutic reagent in tau-mediated neurodegenerative disorders. J Alzheimers Dis 2009.
22. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann Neurol 1997 May;41(5):646-53. (Pubitemid 27212659)
23. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999 Jan;9(1):147-63. (Pubitemid 29056525)
24. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 2001 Dec;79(6):1246-9. (Pubitemid 34019802)
25. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein D, et al. Moderate consumption of Cabernet Sauvignon attenuates Ab neuropathology in a mouse model of Alzheimer's disease. FASEB 2006 Jan 11;in press.
26. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000 Jan 1;9(1):13-25. (Pubitemid 30145284)
27. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996;87(3):493-506. (Pubitemid 26374323)
28. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J 2005 Apr;19(6):659-61. (Pubitemid 40471277)
29. Owen JB, Opii WO, Ramassamy C, Pierce WM, Butterfield DA. Proteomic analysis of brain protein expression levels in NF- [kappa][beta] p50 -/- homozygous knockout mice. Brain Research 2008 Nov 13;1240:22-30.
30. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277(5334):1990-3. (Pubitemid 27449140)
31. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985 Nov;44(6):559-77. (Pubitemid 16196286)
32. Warrick JM, Paulson HL, Gray-Board, Bui QT, Fischbeck KH, Pittman RN, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998 Jun 12;93(6):939-49. (Pubitemid 28280788)
33. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutaminedependent neurodegeneration in Drosophila. Nature 2001 Oct 18;413(6857):739-43. (Pubitemid 33009952)
34. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, et al. Suppression of Huntington's disease pathology in Drosophila by human singlechain Fv antibodies. Proc Natl Acad Sci U S A 2005 Aug 9;102(32):11563-8. (Pubitemid 41153859)
35. Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, et al. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc Natl Acad Sci U S A 2005 Mar 8;102(10):3777-81. (Pubitemid 40354688)
36. Ramaswamy S, McBride J, Kordower J. Animal models of Huntington's disease. ILAR J 2007;48(4):356-73. (Pubitemid 350194368)
37. Siva B, Edirisinghe I, Randolph J, Steinberg F, Kappagoda T. Effect of a polyphenolic extracts of grape seeds on blood pressure in patients with the metabolic syndrome. The FASEB Journal 20, A305-C. 2006. Ref Type: Abstract
38. Bentivegna SS, Whitney KM. Subchronic 3-month oral toxicity study of grape seed and grape skin extracts. Food and Chemical Toxicology 2002 Dec;40(12):1731-43. (Pubitemid 35284143)
39. Ferruzzi MG, Lobo JK, Janle EM, Whittaker N, Cooper B, Simon JE, et al. Bioavailability of Gallic Acid and Catechins from Grape Seed Polyphenol Extract is Improved by Repeated Dosing in Rats: Implications for Treatment in Alzheimer's Disease. J Alzheimers Dis 2009 Jul 20.